

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.

Giorgiana Hatu, François Bailly, Emmanuel Pourcelot, Pierre Pradat, Patrick Mialhes, Marianne Maynard, François Parant, Pierre Chiarello, Jean-Michel Livrozet, Fabien Zoulim, et al.

► **To cite this version:**

Giorgiana Hatu, François Bailly, Emmanuel Pourcelot, Pierre Pradat, Patrick Mialhes, et al.. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.. BMC Infectious Diseases, BioMed Central, 2014, 14 (1), pp.150. <10.1186/1471-2334-14-150>. <inserm-00981317>

HAL Id: inserm-00981317

<http://www.hal.inserm.fr/inserm-00981317>

Submitted on 22 Apr 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients

Giorgiana Hatu^{1,2†}, François Bailly^{1,3,4†}, Emmanuel Pourcelot⁵, Pierre Pradat^{1,3,4*}, Patrick Mialhes^{3,4,6}, Marianne Maynard^{1,3,4}, François Parant⁵, Pierre Chiarello⁷, Jean-Michel Livrozet⁷, Fabien Zoulim^{1,3,4} and Marie-Claude Gagnieu⁵

Abstract

Background: In HIV infected patients, the impact of ribavirin (RBV) pharmacology on sustained virologic response (SVR) to hepatitis C virus (HCV) treatment has not been fully investigated. The objective of this study was to compare the early RBV plasma exposure between a population of HIV-HCV coinfecting patients and an HCV monoinfected group.

Methods: Early RBV plasma exposure (expressed as Area Under the Curve (AUC) from 0 to 4 h) after a 600 mg first dose of RBV was measured in a population of HIV-HCV coinfecting patients in comparison with an HCV monoinfected group. Peripheral blood samples were collected before the 600 mg RBV first dose (T0) to ensure no detectable baseline plasma RBV, and then 30 mn, 1, 2 and 4 hours after RBV intake (T0.5, T1, T2 and T4).

Results: Eighty-six patients with chronic hepatitis C entered the study among whom 23 (27%) were HIV-HCV coinfecting. Coinfecting patients had a significantly lower RBV-AUC_{0-4h} (median: 1469 µg*h/L [range 936–3677]) compared with monoinfected patients (2030 µg*h/L [851–7700]; $p = 0.018$). This RBV under exposure in coinfecting patients persisted after normalization of AUC to RBV dose per kilogram of body weight (182 µg*h/L [110–425] versus 271 µg*h/L [82–1091], $p = 0.001$).

Conclusions: These results suggest that lower early bioavailability of RBV could be one of the reasons for lower SVR in HIV-HCV coinfecting patients treated with pegylated interferon/RBV combination therapy. RBV plasma underexposure seems to be associated with the immunological status of the patients with lower AUC_{0-4h} values observed in the more immunosuppressed coinfecting patients.

Keywords: Hepatitis C, Human immunodeficiency virus, Ribavirin exposure, Treatment, Coinfection

Background

Worldwide prevalence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV) infected patients is about 33%[1-3] and this pathology represents one of the main comorbidities in this population [4,5]. Before the use of protease inhibitors for genotype 1 HCV infection, combination of ribavirin (RBV) and pegylated interferon- α (PEG-IFN) was the standard of care for treatment of chronic HCV patients and it is still

the standard for non-1 genotype infection with or without HIV coinfection. All guidelines to adjust RBV doses have been defined in monoinfected patients but are also used in HIV-HCV ones. According to these guidelines and excepted for genotype 2 or 3 infected patients, RBV doses must be adapted to body weight [6]. Studies have shown that high RBV plasma concentrations could improve early virological response rates [7,8]. However, RBV daily dose, even adjusted for body weight is poorly correlated with RBV plasma concentration [9,10] due to a large inter-individual variability in exposure [11-13]. Different explanations have been proposed for this variability: i) the lean body weight would be a better covariate with a linear influence on RBV clearance

* Correspondence: pierre.pradat@univ-lyon1.fr

†Equal contributors

¹Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 grande rue de la Croix-Rousse, 69004 Lyon, France

³INSERM U1052, Lyon, France

Full list of author information is available at the end of the article

[14]; ii) RBV exposure depends on creatinine clearance [15]; iii) the RBV pharmacokinetics could be impacted by the pharmacological or pathological context of HIV-HCV coinfection [16]. Loustaud-Ratti et al., showed that RBV plasma exposure after a single dose of 600 mg in HCV monoinfected patients was predictive of sustained virological response (SVR) and proposed a threshold of 1755 $\mu\text{g}\cdot\text{h}/\text{L}$ for the RBV plasma AUC from 0 to 4 h post-dose to discriminate patients with subsequent SVR from those with non-response [17]. This is currently the only data that can be used to interpret early RBV exposure and determine the optimal dose to initiate treatment. The impact of the pharmacokinetic properties of RBV in HIV patients has not been fully investigated. As for HCV monoinfected patients, we know that a large inter-individual variability in RBV plasma concentrations exists in HIV-HCV coinfecting patients and that RBV exposure is associated with both efficacy and anemia [8]. Moreover, the SVR rate is known to be lower in HIV-HCV coinfecting than in HCV monoinfected patients. One possible explanation could be that, as for other drugs, HIV infected patients present a lower bioavailability of RBV [18]. The aim of this study was to determine early plasma exposure evaluated by the $\text{AUC}_{0-4\text{h}}$ after a first dose of RBV in a population of HIV-HCV coinfecting patients and to compare the results to those obtained in HCV monoinfected patients.

Methods

Patients

Consecutive patients seen by six physicians during a 12 months period for a chronic hepatitis C infection (Edouard Herriot and Croix-Rousse hospitals, Lyon, France) and initiating a PEG-IFN/RBV therapy between February 2009 and February 2010 entered the study. RBV was taken with light breakfast or snack. Plasma AUC determination after a first dose of RBV (600 mg) was obtained before therapy initiation as described by Loustaud-Ratti et al. [17] to evaluate RBV bioavailability. Treatment was then initiated using a weight-based RBV dose after possible adaptation following the AUC results. Patients with low ribavirin exposure (as assessed by AUC result) were usually treated with a 200 mg higher ribavirin dose. Patients were divided into two groups according to their HIV status. To be included, patients had to have detectable HCV RNA, and for HIV-HCV coinfecting patients to be on combined antiretroviral therapy (cART) for at least one month prior to RBV initiation. Patients with RBV treatment within the past three months were excluded. All patients gave their informed consent before they entered the study. Following characteristics were recorded at baseline (day of the first RBV dose intake): age, body weight, body mass index (BMI), creatinine level, glomerular filtration rate (GFR,

estimated by Cockcroft clearance and Modification of the Diet in Renal Disease (MDRD) formula), hemoglobin, aminotransferases, fibrosis stage, HCV genotype, HCV- and HIV RNA quantification, CD4 level and antiretroviral drugs.

Methods

The plasma AUC was determined for each patient before the antiviral treatment or at the first day. Patients received a single RBV dose of 600 mg (T_0) and peripheral blood samples were collected before the administration to ensure undetectable baseline plasma RBV, and then 30 mn, 1, 2 and 4 hours after RBV intake ($T_{0.5}$, T_1 , T_2 and T_4). To avoid RBV exchange between plasma and red blood cells, samples were placed in ice immediately after withdrawal and centrifuged as soon as possible (maximum lag time was 1 h). RBV plasma concentrations were measured using a validated High-Performance Liquid Chromatography-Diode Array Detector method [19]. This method is highly specific, sensible (limit of quantification = 0.05 mg/L), and precise (total imprecision, calculated by measuring the coefficient of variation (CV) of the internal quality control values was less than 10% for concentrations from 0.20 to 5.00 mg/L).

Pharmacokinetic analysis

RBV AUC was calculated using the Table Curve 2D software (Systat Software Inc). As a large variability of body weight (BW) was observed and that all patients received the same RBV first dose, AUC were also normalized as $\text{AUC}_{0-4\text{h}}/\text{dose}$ (in mg/BW in kg). Results of AUC and normalized AUC were analyzed according to the two groups defined by the HIV status.

Statistical analysis

All quantitative variables were expressed as median and range. Comparisons of data were made using the non-parametric Mann-Whitney test. Statistical analysis was performed using the Statistica® software package (StatSoft Inc). A multivariate logistic regression analysis was conducted to identify factors potentially associated with RBV underexposure (defined by an $\text{AUC} < 1755 \mu\text{g}\cdot\text{h}/\text{L}$). Variables significantly associated with RBV underexposure in univariate analysis and variables suspected to be associated with it, were included in the multivariate model. A p value below 0.05 was considered as statistically significant.

Ethical considerations

RBV pharmacokinetics monitoring is routinely performed in our unit for patients treated with PEG-IFN/RBV. This monitoring includes measurement of RBV AUC before therapy initiation and assessment of RBV plasma concentration during treatment. RBV monitoring is used to adapt

RBV dose and to manage anemia. According to the French legislation (Public Health Code modified by the law no. 2004–806, 9 August 2004 and the Huriot–Sérusclat act 88–1138, 20 December 1988) and since this study was observational, no ethics committee approval was necessary.

Results

Eighty-six Caucasian patients with chronic hepatitis C entered the study. Among them, 62 were males (72%) and 23 (27%) were HIV-HCV coinfectd. Most of them (85%) were infected with HCV genotype 1 or 4. Baseline characteristics are presented in Table 1.

Among HIV-HCV coinfectd patients, 20/23 (87%) had a negative HIV RNA viral load at baseline (<50 copies/mL) and 57% had a CD4 count above 500 cells/mm³. Most of them received two nucleoside reverse transcriptase inhibitors (NRTIs) (22 patients): tenofovir and emtricitabine for 20 of them (91%) and didanosine associated with stavudine or tenofovir for two. One patient received

a cART regimen without NRTI. No patient received abacavir. Nucleoside treatment was associated with a protease inhibitor in 14 patients: seven patients received lopinavir, four darunavir, two atazanavir and one saquinavir. All these patients were also treated with ritonavir as a booster. Eight patients received a non-nucleoside reverse transcriptase inhibitor (NNRTI): four nevirapine, three efavirenz and one etravirine.

Finally, four patients received raltegravir, associated with a protease inhibitor regimen in three of them and with tenofovir and emtricitabine in one. One patient received maraviroc in association with a protease inhibitor, NNRTI and raltegravir.

Medians of AUC_{0-4h} and AUC_{0-4h} normalized to the first RBV dose expressed in mg/kg BW were 1469 µg.h/L and 182 (µg.h/L)/(mg/kg) respectively. According to the threshold of 1755 µg.h/L defined in HCV monoinfected patients, 14/23 (61%) coinfectd patients were found to have an AUC_{0-4h} below this value. No significant

Table 1 Main baseline characteristics of HCV monoinfected and HIV-HCV coinfectd patients (n = 86)

| Characteristics | HCV (n = 63) | HIV-HCV (n = 23) | p value |
|--|-------------------|-------------------|--------------|
| Gender ratio (M/F) | 2.0 | 6.7 | 0.063 |
| Age (years) | 50 (23–74) | 46 (35–60) | 0.066 |
| Body weight (kg) | 75 (41–130) | 69 (52–96) | 0.032 |
| Men body weight (kg) | 79 (44–130) | 69 (52–96) | 0.008 |
| Body mass index (BMI) | 25.7 (16.4–43.3) | 22.1 (17.6–32.8) | 0.003 |
| Men body mass index (BMI) | 25.8 (18.4–43.3) | 22.2 (17.6–32.8) | 0.002 |
| Creatinine (µmol/L) | 76 (49–189) | 82 (45–123) | 0.164 |
| Cockroft clearance (mL/min) | 105.7 (44–257.7) | 90.2 (67.2–202.9) | 0.244 |
| MDRD (mL/min) | 90.9 (34.2–167.5) | 89.5 (58.2–144.7) | 0.880 |
| ALT (IU/mL) | 62 (20–383) | 60.5 (20–1492) | 0.853 |
| AST (IU/mL) | 47 (20–402) | 57 (26–969) | 0.485 |
| HCV RNA (log IU/mL) | 6.1 (3.59–6.99) | 6.4 (2.81–7.39) | 0.111 |
| Hemoglobin level (g/dl) | 14.5 (8.2–17.2) | 15.2 (12.1–18.8) | 0.036 |
| Men hemoglobin level (g/dl) | 15 (8.3–17.2) | 15.2 (12.1–18.8) | 0.239 |
| HCV genotype n (%) | | | 0.566 |
| 1 | 48 (76) | 14 (61) | |
| 2 | 2 (3) | 1 (4) | |
| 3 | 6 (10) | 4 (17) | |
| 4 | 7 (11) | 4 (17) | |
| Fibrosis score (Metavir) n (%) | | | 0.780 |
| 0 – 2 | 29 (46) | 12 (52) | |
| 3 – 4 | 34 (54) | 11 (48) | |
| HCV treatment status at baseline n (%) | | | 0.434 |
| HCV treatment naive | 19 (30) | 9 (41) | |
| Nonresponders | 25 (40) | 9 (41) | |
| Relapsers | 19 (30) | 4 (18) | |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; MDRD, Modification of the Diet in Renal Disease. Bold style indicates statistical significance. Quantitative variables are expressed as median and range.

difference was found for cART type and duration, HIV viral load and CD4 level between the 2 sub-groups of HIV-HCV coinfecting patients defined by this threshold (Table 2). All three patients found to have a detectable HIV RNA, had an AUC_{0-4h} below 1755 µg.h/L. With regard to the immune status, 61% of patients had a CD4 level below the retained cutoff of 500/mm³. Interestingly, the AUC_{0-4h} was significantly lower for these patients than for those with CD4 level greater than 500/mm³ with values of 1270 µg.h/L and 1840 µg.h/L respectively (p = 0.047). For these 2 sub-groups of coinfecting patients, normalized AUC were 144 and 195 (µg.h/L)/(mg/kg) but the difference did not reach statistical significance. Table 3 summarizes these results.

For the reference group of HCV monoinfected patients, median AUC_{0-4h} and normalized AUC_{0-4h} were 2030 µg.h/L and 271 µg.h/L respectively. In comparison to HIV-HCV coinfecting patients, these two parameters were significantly higher (p = 0.018 and 0.001, respectively). Sixty-eight percent of monoinfected patients had an AUC_{0-4h} above the threshold of 1755 µg.h/L vs 39% of HIV-HCV coinfecting patients (p = 0.014). The median AUC_{0-4h} was slightly higher in naive HCV patients than in relapsers and non-responders (2434 µg.h/L, 2025 µg.h/L and 1873 µg.h/L, respectively, although this difference did not reach statistical significance (p = 0.165).

Different factors potentially associated with RBV pharmacokinetics variability were investigated. Except for body weight, BMI, and hemoglobin level, baseline characteristics did not differ between monoinfected and coinfecting patients. Median body weight and BMI were lower in coinfecting patients than in monoinfected ones (69 kg vs 75 kg, p = 0.032 and 22.1 vs 25.7, p = 0.003, respectively). Conversely, hemoglobin level was lower in monoinfected patients (median 14.5 g/dl) than in coinfecting patients (15.2 g/dl; p = 0.036).

Multivariate logistic regression analysis indicated that presence of HIV coinfection (OR = 3.76, 95% CI [1.21-11.6]; p = 0.022) and male gender (OR = 4.59, 95% CI [1.15-18.3]; p = 0.031) were independently associated with RBV underexposure (Table 4).

Discussion

Using the AUC_{0-4h} method, our results clearly showed a plasma underexposure in HIV-HCV coinfecting patients after a single dose intake of RBV in comparison with monoinfected patients. The pharmacokinetics of RBV is less documented in HIV-HCV coinfecting patients than in monoinfected ones but some studies showed that the achievement of RBV cutoffs was a predictive factor of SVR independent of HIV coinfection [20,21]. The heterogeneity of our cohort of HIV-HCV coinfecting patients was representative of a treated HIV population in a hospital environment (57% with CD4 > 500 cells/mm³; 87% with undetectable HIV viral load under HAART; patients mainly under 2 NRTIs + 1 boosted protease inhibitor) [22]. The choice of AUC_{0-4h} was made in accordance with the study of Loustaud-Ratti *et al.* for HCV monoinfected patients [17]. Indeed, the authors showed that the abbreviated AUC_{0-4h} was highly correlated to the full AUC_{0-12h} because it described the main inter-individual variability of RBV pharmacokinetic parameters (i.e. absorption and distribution phases). Interestingly in our study, more than 60% of coinfecting patients had an AUC_{0-4h} below the threshold of 1755 µg.h/L defined as associated with SVR in HCV monoinfected patients [17]. In comparison, only 32% of monoinfected patients of our study had an AUC_{0-4h} below this value. Demographic or biological parameters were collected in order to detect confounding factors that could affect differences in early RBV exposure between both populations. Some differences were found. The first of

Table 2 Particular characteristics of HIV-HCV coinfecting patients according to RBV AUC_{0-4h} threshold (n = 23)

| | All (n = 23) | RBV AUC _{0-4h} <1755 µg.h/L (n = 14) | RBV AUC _{0-4h} >1755 µg.h/L (n = 9) | p value |
|--|----------------|---|--|---------|
| HIV RNA <50 copies/mL, n (%) | 20 (87) | 11 (79) | 9 (100) | 0.253 |
| HIV RNA copies/mL | 50 (20-9850) | 50 (20-9850) | 50 (40-50) | 0.687 |
| CD4 (cells/mm ³) | 543 (325-1067) | 498 (325-993) | 543 (368-1067) | 0.614 |
| CD4% | 30 (10-48) | 29.5 (10-48) | 32 (27-45) | 0.174 |
| Duration of HIV treatment (years) | 11 (1-19) | 11 (1-16) | 10 (2-19) | 0.825 |
| Antiretroviral therapy, n (%) | | | | |
| Protease inhibitor | 14 (61) | 7 (50) | 7 (78) | |
| Nucleoside reverse transcriptase inhibitor (NRTI) | 21 (91) | 13 (93) | 8 (89) | |
| Non-nucleoside reverse transcriptase inhibitor (NNRTI) | 8 (35) | 6 (43) | 2 (22) | |
| Integrase inhibitor | 4 (17) | 1 (<1) | 3 (33) | |
| Receptor CCR5 inhibitor | 1 (<1) | 0 | 1 (11) | |

Quantitative variables are expressed as median and range.

Table 3 AUC_{0-4h} and normalized AUC_{0-4h} to RBV 600 mg/body weight

| | HCV (n = 63) | HIV-HCV (n = 23) | p value |
|---|-----------------|---------------------|------------------|
| AUC _{0-4h} (µg.h/L) | 2030 (851-7700) | 1469 (936-3677) | 0.018 |
| Patients with AUC _{0-4h} <1755 (%) | 32 | 61 | 0.014 |
| Men AUC _{0-4h} (µg.h/L) | 1875 (850-7700) | 1414 (1034-3677) | 0.050 |
| Men with AUC _{0-4h} <1755 (%) | 43 | 65 | 0.103 |
| Normalized AUC _{0-4h} (µg.h/L)/(mg/kg) | 271 (82-1091) | 182 (110-425) | 0.001 |
| Men normalized AUC _{0-4h} (µg.h/L)/(mg/kg) | 266 (82-1091) | 173 (110-425) | 0.004 |
| | | CD4 < 500 | CD4 ≥ 500 |
| AUC _{0-4h} | | 1270 (936-2792) | 1840 (1280-3677) |
| Normalized AUC _{0-4h} | | 144 (110-425) | 195 (154-349) |

Quantitative variables are expressed as median and range. Bold style indicates statistical significance.

them was a body weight significantly lower for coinfecting patients. As the initial RBV dose was the same (600 mg) for all patients, irrespectively of this parameter, early exposure was normalized for RBV dose expressed as mg/kg BW. Normalized AUC_{0-4h} remained significantly different between both groups. In addition, hemoglobin level was higher in coinfecting than in mono-infected patients. It is well known that RBV is highly concentrated in red blood cells [23], but this parameter was not expected to influence AUC_{0-4h} which was determined after a single dose of RBV. Among other parameters known to have an influence on RBV exposure is the renal function, but neither median baseline serum creatinine, nor estimated glomerular filtration rate (GFR) calculated by Cockcroft-Gault equation or MDRD formula, differed significantly between both groups (Table 1). We have determined early RBV exposure regardless of HCV genotype as no difference was observed in the genotype distribution in each of the two populations of this study and because we wanted to evaluate early bioavailability of RBV independently of the subsequent treatment response. In the study by Loustaud-Ratti *et al.* the population was exclusively constituted of mono-infected HCV genotype 1 patients. This is the main difference with our study in which genotypes 1 to 4 were present but with a majority of genotype 1. Indeed, except for this parameter and for the distribution of fibrosis

score, baseline characteristics were similar in both studies. However, 32% of our HCV mono-infected patients had an AUC_{0-4h} below the 1755 µg.h/L threshold compared with 58% in this historical study. This difference could be explained by the presence of patients infected by HCV genotype 2, 3 or 4 because only two of these 15 patients had an AUC_{0-4h} below this threshold. Finally, we found a strong gender ratio in favor of male patients in our coinfecting population. In order to estimate if gender could affect RBV exposure, we compared parameters which were statistically different in the whole population. For body weight the significant difference was even more important and as expected, this parameter was lower in coinfecting patients (Table 1). Hence the interest of the AUC normalized to the first RBV dose deletes the weight effect. Conversely, differences in hemoglobin level were no longer significant due to the higher proportion of women in the mono-infected group. In spite of the reduced number of patients, the difference of AUC_{0-4h} or normalized AUC_{0-4h} between mono-infected and coinfecting male patients was statistically significant, and the proportion of AUC under the 1755 µg.h/L threshold remained high. No other differences in demographic or biological characteristics were found between the two populations of this study.

Given that there was a strong gender ratio in favor of male patients and in order to see if gender could affect

Table 4 Univariate and multivariate logistic regression analysis to identify factors potentially associated with ribavirin underexposure (defined by an AUC < 1755 µg.h/L)

| | Univariate analysis | | Multivariate analysis | |
|-----------------------------|-------------------------|--------------|-------------------------|--------------|
| | OR (95% CI) | p | OR (95% CI) | p |
| HIV coinfection (yes vs no) | 3.34 (1.24-9.01) | 0.017 | 3.76 (1.21-11.6) | 0.022 |
| Gender (male vs female) | 7.00 (1.89-25.9) | 0.004 | 4.59 (1.15-18.3) | 0.031 |
| Weight | 1.03 (0.99-1.06) | 0.067 | 1.03 (0.99-1.08) | 0.142 |
| Age | 0.97 (0.93-1.01) | 0.160 | - | - |
| MDRD | 1.00 (0.98-1.02) | 0.803 | - | - |
| Cockcroft | 1.01 (0.99-1.02) | 0.145 | 1.00 (0.98-1.02) | 0.927 |

Bold style indicates statistical significance.

our results, we compared AUC_{0-4h} between mono-infected and coinfected male patients. It is noteworthy that 43% of mono-infected and 65% of coinfected male patients had AUC_{0-4h} below the 1755 $\mu\text{g}\cdot\text{h}/\text{L}$ threshold, although this difference did not reach statistical significance ($p = 0.103$). As expected, among HCV mono-infected patients, the AUC_{0-4h} was slightly higher in naive patients than in relapsers and non-responders to a previous treatment although this difference did not reach statistical significance probably because of a limited number of patients in each subgroup.

Unexpectedly, RBV plasma underexposure seems to be associated with the immunological level of HIV patients. RBV exposure was indeed better if CD4 cell count was greater than $500/\text{mm}^3$. In the RIBAVIC study, using PEG-IFN/RBV therapy in HIV co-infected patients, a trend for a lower SVR was noted in patients with a CD4 cell count under 500 versus patients upper this threshold (21% vs 33%, respectively; $p = 0.051$) [24]. Then, in the PRESCO trial, a higher dosing of ribavirin (weight-based dosing with 1000 to 1200 mg) was associated with better SVR rates but higher risk of anemia [25]. In the present study, when the immunorestitution under cART was considered complete, i.e. with a CD4 cell count $> 500/\text{mm}^3$, RBV exposure was similar in this HIV sub-group in comparison with HCV mono-infected population.

Food intake is known to potentially impact RBV bio-availability. Both the AUC_{tf} (from time zero to the time of the final quantifiable sample) and C_{max} of a single oral dose of ribavirin were indeed shown to be increased by co-administration of a high fat meal [26]. However, in the present study all patients received RBV with light breakfast or snack which suggests no bias between mono- and coinfected patients.

Conclusion

In conclusion, HIV-HCV coinfected patients present a lower RBV exposure which could at least in part explain the lower response rate of these patients to HCV treatment. This hypothesis should be further investigated on a larger number of coinfected patients focusing on the immune status of these patients. In the past, recommendations were to use low dose of RBV in HIV patients in order to avoid toxicity associated with antiretroviral drugs, such as zidovudine, stavudine or didanosine [27,28]. However, these drugs are progressively neglected to the benefit of less cytotoxic new antiretroviral drugs. So, higher doses of RBV can be used to improve SVR in coinfected patients, as suggested in several studies [7,29]. Measurement of early RBV exposure by determination of AUC_{0-4h} possibly followed by RBV dose adjustment could help in optimizing antiviral therapy in HIV-HCV coinfected patients, particularly in the more immunosuppressed ones because RBV underexposure was noted in this specific sub-group.

Abbreviations

AUC: Area under the curve; BMI: Body mass index; cART: Effective combination antiretroviral therapy; GFR: Glomerular filtration rate; HAART: Highly active antiretroviral therapy; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; MDRD: Modification of the diet in renal disease; RBV: Ribavirin; SVR: Sustained virological response.

Competing interests

Fabien Zoulim received consulting/speaker fees from Gilead Science, Bristol Myers Squibb, and Roche. François Bailly received speaker fees from Janssen. The other authors have no conflict of interests to declare. No financial support.

Authors' contributions

FB, PP, MM, FP, FZ, MCG participated in the conception and design of the study. GH, FB, EP, PP, PM, MM, FP, PC, JML participated in data collection. EP and PP performed the statistical analysis. GH, FB, EP, PP, PM and MCG helped to draft the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgments

The authors gratefully thank Laurent Cotte, Philippe Lack, François Jeanblanc, Djamilia Makhloufi, Sylvie Radenne, and Isabelle Schlienger for their contribution in this study.

Author details

¹Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 grande rue de la Croix-Rousse, 69004 Lyon, France. ²Université de Médecine et Pharmacie "Iuliu Hatieganu", Cluj-Napoca, Romania. ³INSERM U1052, Lyon, France. ⁴Université Lyon I, Lyon, France. ⁵Pharmacology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. ⁶Département of Infectious Diseases, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. ⁷Department of Immunology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Received: 26 November 2013 Accepted: 14 March 2014

Published: 20 March 2014

References

1. Sherman KE, Rouster SD, Chung RT, Rajicic N: **Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.** *Clin Infect Dis* 2002, **34**(6):831–837.
2. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL: **Hepatitis C and progression of HIV disease.** *JAMA* 2002, **288**(2):199–206.
3. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE: **Correlates of hepatitis C virus infections among injection drug users.** *Medicine (Baltimore)* 1995, **74**(4):212–220.
4. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P: **Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).** *AIDS* 2003, **17**(12):1803–1809.
5. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M: **Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus.** *Clin Infect Dis* 2001, **33**(10):1793–1795.
6. Clinical Practice Guidelines EASL: **Management of hepatitis C virus infection.** *J Hepatol* 2014, **60**(2):392–420.
7. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R: **High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.** *Hepatology* 2005, **41**(2):275–279.
8. Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V: **Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.** *J Acquir Immune Defic Syndr* 2005, **39**(4):401–405.
9. Crespo M, Pou L, Esteban JI, Falco V, Ribera E, Lopez R, Sauleda S, Curran A, Villar Del Saz S, Feijoo M, Ocana I, Pahissa A: **Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.** *Antivir Ther* 2007, **12**(8):1217–1223.
10. Jen J, Laughlin M, Chung C, Heft S, Afrime MB, Gupta SK, Glue P, Hajian G: **Ribavirin dosing in chronic hepatitis C: application of population**

- pharmacokinetic-pharmacodynamic models. *Clin Pharmacol Ther* 2002, **72**(4):349–361.
11. Glue P: **The clinical pharmacology of ribavirin.** *Semin Liver Dis* 1999, **19**(Suppl 1):17–24.
 12. Jen JF, Glue P, Gupta S, Zambas D, Hajjan G: **Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.** *Ther Drug Monit* 2000, **22**(5):555–565.
 13. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C: **Ribavirin quantification in combination treatment of chronic hepatitis C.** *Antimicrob Agents Chemother* 2003, **47**(1):124–129.
 14. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K: **Pharmacokinetics of ribavirin in patients with hepatitis C virus.** *Br J Clin Pharmacol* 2006, **62**(6):710–714.
 15. Bruchfeld A, Lindahl K, Schvarz R, Stahle L: **Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.** *Ther Drug Monit* 2002, **24**(6):701–708.
 16. Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH: **Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.** *J Hepatol* 2007, **47**(1):23–30.
 17. Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Cales P, Lefebvre A, Fauchais AL, Liozon E, Vidal E: **Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.** *Hepatology* 2008, **47**(5):1453–1461.
 18. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Gunthard HF, Rentsch K, Buclin T, Aouir M, Telenti A, Decosterd LA, Rotger M, Csajka C: **Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.** *Antimicrob Agents Chemother* 2012, **56**(6):2959–2966.
 19. Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P: **Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.** *Ther Drug Monit* 2009, **31**(3):374–381.
 20. Aguilar Marucco D, Gonzalez De Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G: **The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.** *J Antimicrob Chemother* 2008, **61**(4):919–924.
 21. Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P: **Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.** *Antivir Ther* 2011, **16**(8):1317–1326.
 22. Sulkowski MS, Benhamou Y: **Therapeutic issues in HIV/HCV-coinfected patients.** *J Viral Hepat* 2007, **14**(6):371–386.
 23. Souvignet C, Maynard M, Gagnieu MC, Trepo C: **Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?** *J Hepatol* 2007, **47**(1):1–3.
 24. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C: **Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.** *JAMA* 2004, **292**(23):2839–2848.
 25. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Si, San Joaquin I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, Garcia-Samaniego J, Soriano V: **Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.** *AIDS Res Hum Retroviruses* 2007, **23**(8):972–982.
 26. **Ribavirin - Summary of Product Characteristics - European Medicines Agency.** http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf (visited February 2014).
 27. Lafeuillade A, Hittinger G, Chadapaud S: **Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.** *Lancet* 2001, **357**(9252):280–281.
 28. Moreno A, Queda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Barcena R, Moreno S: **High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.** *Antivir Ther* 2004, **9**(1):133–138.
 29. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rockstroh J: **Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.** *AIDS* 2007, **21**(9):1073–1089.

doi:10.1186/1471-2334-14-150

Cite this article as: Hatu et al.: Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. *BMC Infectious Diseases* 2014 **14**:150.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

